Medical Marijuana for HIV/AIDS in Washington State

HIV/AIDS is one of Washington State's explicitly named qualifying conditions for medical marijuana. Cannabis has been used medically by HIV patients since the early days of the epidemic, and research over the past three decades has established several evidence-backed applications — particularly for neuropathy, wasting, and antiretroviral side effects.

Does HIV/AIDS qualify for Washington medical marijuana?

Yes. Washington's medical cannabis statute (RCW 69.51A) lists HIV/AIDS as a qualifying condition. Any confirmed HIV diagnosis satisfies this requirement — you do not need to have advanced disease or a specific CD4 count. Both HIV and AIDS stages qualify.

How cannabis helps HIV patients

• HIV-associated neuropathy — peripheral neuropathy (numbness, burning, pain in hands and feet) affects a large percentage of HIV patients, both from the virus itself and from older antiretroviral drugs. Multiple randomized controlled trials show cannabis significantly reduces HIV neuropathy pain — including a landmark UCSF study that found vaporized cannabis reduced neuropathic pain by 34% compared to 17% for placebo.
• HIV wasting syndrome — dronabinol (synthetic THC) is FDA-approved for HIV-related wasting. Natural cannabis with THC has appetite-stimulating effects that can help prevent or reverse unintended weight loss.
• Antiretroviral side effects — modern antiretrovirals (ARVs) are well-tolerated compared to earlier drugs, but some patients still experience nausea, fatigue, and GI symptoms. Cannabis effectively manages these side effects.
• Mental health — depression, anxiety, and PTSD rates are elevated in HIV patients. Cannabis addresses these without the contraindicated drug interactions of some psychiatric medications.
• Sleep disruption — common in HIV patients and often undertreated. Cannabis improves sleep quality and duration for many patients.

Drug interactions with antiretrovirals

This is an important consideration. Some antiretrovirals are metabolized by CYP3A4 and CYP2D6 enzymes, which cannabinoids can inhibit or induce at higher doses. The clinical significance of most cannabis-ARV interactions is low at typical cannabis doses, but a few combinations warrant attention:

• Protease inhibitors (atazanavir, darunavir, ritonavir) — ritonavir in particular is both a CYP3A4 inhibitor and a potent inducer at high concentrations, making interactions unpredictable; monitor for toxicity or reduced efficacy
• Integrase inhibitors (bictegravir, dolutegravir, raltegravir) — generally lower interaction risk
• NNRTIs (efavirenz) — efavirenz itself is a CYP2B6 inducer; cannabis interaction is generally low risk

Share your full ARV regimen with your Green Wellness provider at your evaluation so they can flag any potential interactions.

Getting your authorization

Bring documentation of your HIV diagnosis — a letter from your infectious disease provider, HIV specialist, or a recent lab result showing HIV-positive status. Your Green Wellness provider will review your ARV regimen and discuss appropriate cannabis approaches for your specific situation.

Green Wellness evaluations are fully protected under HIPAA. Your HIV status is not shared with employers, insurers, or any third party without your written consent.

Book your HIV/AIDS evaluation — $175 →